Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 661-668

  Varker, Kimberly A ^a   Campbell, Jacqueline ^a   Shah, Manisha H ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Anti angiogenic therapy; Carcinoid tumor; Islet cell tumor; Phase II trial; Thalidomide

Indexed keywords

PANCREASTATIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; ATAXIA; CANCER GROWTH; CANCER PATIENT; CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEMORRHAGIC CYSTITIS; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; MALE; MOTOR NEUROPATHY; ORTHOSTATIC HYPOTENSION; PANCREAS ISLET CELL CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT DURATION; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADENOMA, ISLET CELL; ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOID TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC HORMONES; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 38049008967     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0521-9     Document Type: Article

References (27)

1. Baidas SM, Winer EP, Fleming GF et al (2000) Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18:2710-2717
2. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322
3. Calhoun D, Toth-Fejel S, Cheek J et al (2003) Serum peptide profiles in patients with carcinoid tumors. Am J Surg 186:28-31
4. Creutzfeldt W, Bartsch HH, Jacubaschke U et al (1991) Treatment of gastrointestinal endocrine tumors with interferon-alpha and octeotide. Acta Oncol 30:529-535
5. Drake MJ, Robson W, Mehta P et al (2003) An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88:822-827
6. Drougas JG, Johnson CM, McKusick MA et al (1998) Hepatic artery chemoembolization for management of paients with advanced metastatic carcinoid tumors. Am J Surg 175:408-412
7. Eisen T, Boshoff C, Mark I et al (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812-817
8. Escudier B, Lassau N, Couanet D et al (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029-1035
9. Fehniger TA, Shah MH, Turner MJ et al (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162:4511-4520
10. Fife K, Howard MR, Gracie F et al (1998) Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 9:751-755
11. Fine HA, Figg WD, Jaeckle K et al (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715
12. Goebel SU, Serrano J, Yu Fang et al (1999) Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85:1470-1483
13. Haslett PA, Corral LG, Albert M et al (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885-1892
14. Hwu WJ, Krown SE, Menell JH et al (2003) Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-3356
15. Kloppel G, Heitz P, Capella C et al (1996) Pathology and nomenclature of Human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 20:132-141
16. Kulke MH, Stuart K, Enzinger PC et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406
17. Lin AY, Brophy N, Fisher GA et al (2005) Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 103:119-125
18. Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin- doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8):519-523
19. Motzer RJ, Berg W, Ginsberg M et al (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302-306
20. Oliver SJ, Moreira A, Kaplan G (2000) Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 97:109-120
21. Pujol JL, Breton JL, Gervais B et al (2006) A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): an intergroup study FNCKCC Cleo04-IFCT 00-01. Presented at the American Society of Clinical Oncology, abstract #7057
22. Rowland TL, McHugh SM, Deighton J et al (1998) Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacol 40:11-20
23. Rowland TL, McHugh SM, Deighton J et al (1999) Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor α by thalidomide: comparisons with dexamethasone. Immunol Lett 68:325-332
24. Raut CP, Kulke MH, Glickman JN et al (2006) Carcinoid tumors. Curr Probl Surg 43:383-450
25. Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myelomas. Cancer Treat Rev 26:351-362
26. Rubin J, Ajani J, Schirmer W et al (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600-606
27. Tseng JE, Glisson BS, Khuri FR et al (2001) Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92:2364-2373